Health
UK Risks Critical Medicine Shortage as EU Lures Drugmakers
- Britain should encourage generics investment: Sandoz’s UK head
- Swiss company says government is sidelining generics industry
This article is for subscribers only.
Britain risks running out of critical medicines because it’s failing to stay competitive on generics, according to the UK head of one of the industry leaders.
The European Union last year proposed legislation to fund new investments and repatriate production of drugs deemed essential. If the UK doesn’t take steps to make the country attractive to companies, it will face further shortages, said Diane DiGangi Trench, who heads Sandoz Group AG in the UK.